295 related articles for article (PubMed ID: 16735371)
1. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
2. [Effect of cyclooxygenase-2,and matrix metalloproteinase-2 expression on prognosis of lung cancer].
Zhang HZ; Lu ZQ; Xie DR; Li HG; Xiong LH; Zhang H; Chen XB
Ai Zheng; 2004 Oct; 23(10):1190-3. PubMed ID: 15473933
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
Li L; Mei TH; Zhou XD; Zhang XG
Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
[TBL] [Abstract][Full Text] [Related]
4. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
6. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
7. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
[TBL] [Abstract][Full Text] [Related]
9. [Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma].
Zhang HZ; Wei YP; Li HG; Wang M; Liu JG; Wu C
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1307-10. PubMed ID: 16982442
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
Passlick B; Sienel W; Seen-Hibler R; Wöckel W; Thetter O; Mutschler W; Pantel K
Clin Cancer Res; 2000 Oct; 6(10):3944-8. PubMed ID: 11051242
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
Milas I; Komaki R; Hachiya T; Bubb RS; Ro JY; Langford L; Sawaya R; Putnam JB; Allen P; Cox JD; McDonnell TJ; Brock W; Hong WK; Roth JA; Milas L
Clin Cancer Res; 2003 Mar; 9(3):1070-6. PubMed ID: 12631609
[TBL] [Abstract][Full Text] [Related]
12. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
[TBL] [Abstract][Full Text] [Related]
13. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
Shou Y; Hirano T; Gong Y; Kato Y; Yoshida K; Ohira T; Ikeda N; Konaka C; Ebihara Y; Zhao F; Kato H
Br J Cancer; 2001 Nov; 85(11):1706-12. PubMed ID: 11742492
[TBL] [Abstract][Full Text] [Related]
14. [Overexpression of COX-2 and its clinical significance in non-small cell lung cancer].
Tian F; Wang TY; Gong M; Lu XM; Hu J; Wang J; Zhang CH
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):407-10. PubMed ID: 12895344
[TBL] [Abstract][Full Text] [Related]
15. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma.
Wang Y; Fang S; Wei L; Wang R; Jin X; Wen D; Li Y; Guo W; Wang N; Zhang J
Lung Cancer; 2005 Aug; 49(2):155-61. PubMed ID: 15949868
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer].
Fang SM; Jin X; Li Y; Wang R; Guo W; Wang N; Zhang JH
Ai Zheng; 2005 Mar; 24(3):305-10. PubMed ID: 15757531
[TBL] [Abstract][Full Text] [Related]
18. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival.
Zheng S; Chang Y; Hodges KB; Sun Y; Ma X; Xue Y; Williamson SR; Lopez-Beltran A; Montironi R; Cheng L
Anticancer Res; 2010 Mar; 30(3):713-8. PubMed ID: 20392988
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
[TBL] [Abstract][Full Text] [Related]
20. [Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance].
Luo CF; Zhu RQ; Wang H; Lu YL
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):526-30. PubMed ID: 18069634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
